Minerva Neurosciences (NASDAQ:NERV – Get Free Report) and Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.
Earnings and Valuation
This table compares Minerva Neurosciences and Xenetic Biosciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Minerva Neurosciences | N/A | N/A | $1.44 million | ($1.85) | -2.17 |
| Xenetic Biosciences | $2.50 million | 2.04 | -$3.96 million | ($2.05) | -1.09 |
Institutional & Insider Ownership
34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 10.4% of Minerva Neurosciences shares are held by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and target prices for Minerva Neurosciences and Xenetic Biosciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Minerva Neurosciences | 1 | 1 | 0 | 0 | 1.50 |
| Xenetic Biosciences | 1 | 1 | 0 | 0 | 1.50 |
Minerva Neurosciences currently has a consensus target price of $4.00, suggesting a potential downside of 0.25%. Given Minerva Neurosciences’ higher possible upside, equities analysts clearly believe Minerva Neurosciences is more favorable than Xenetic Biosciences.
Volatility and Risk
Minerva Neurosciences has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500.
Profitability
This table compares Minerva Neurosciences and Xenetic Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Minerva Neurosciences | N/A | -41.35% | -43.68% |
| Xenetic Biosciences | -110.42% | -64.66% | -54.63% |
Summary
Minerva Neurosciences beats Xenetic Biosciences on 8 of the 11 factors compared between the two stocks.
About Minerva Neurosciences
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
